Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients

Table 3 Vertebral fracture correlated with background features, eGFR, and levels of bone-metabolism-related markers

	Univariate logistic regression OR (95% CI)	Multivariate logistic regression OR (95% CI)
Age (per increase in 1 year)	1.13 (1.03-1.24)	1.13 (1.02-1.26)
Female (Male is reference)	1.87 (0.53-6.62)
Diabetes mellitus (nondiabetes is reference)	0.88 (0.24-3.22)
BMI (per increase in 1)	1.07 (0.83-1.37)
eGFR (per increase in 1 ml/min/1.73 m²)	0.97 (0.95-1.00)	1.03 (0.98-1.08)
Calcium level (per increase in 1 mmol/l)	0.63 (0.005-72.0)
Phosphate level (per increase in 1 mmol/l)	1.38 (0.10-18.86)
Ln(iPTH) (per increase in 1)	1.38 (0.59-3.23)
1,25(OH)₂D level (per increase in 1 pmol/l)	0.98 (0.97-1.00)
Ln(FGF23) (per increase in 1)	2.70 (1.27-5.74)	4.44 (1.13-17.46)
ALP level (per increase in 1 U/l)	1.00 (0.99-1.01)
Urinary NTX level (per increase in 1 nmol.BCE/mmol.Cr)	1.00 (0.98-1.03)

Multivariate logistic regression OR was determined from a logistic regression model that includes age, eGFR, and ln(FGF23) as variables.
Abbreviations: OR odds ratio; CI confidence interval; BMI body mass index; eGFR estimated glomerular filtration rate; ln(iPTH) natural logarithm value of intact parathyroid hormone level; 1,25(OH) ₂ D 1,25(OH)₂ vitamin D; ln(FGF23) natural logarithm value of fibroblast growth factor 23 level; ALP alkaline phosphatase; urinary NTX urinary N-terminal telopeptide.

ISSN: 1471-2369